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Abstract
In the field of neuroimaging reverse inferences can lead us to suppose the involve-
ment of cognitive processes from certain patterns of brain activity. However, the
same reasoning holds if we substitute “brain activity” with “brain alteration” and “cog-
nitive process” with “brain disorder.” The fact that different brain disorders exhibit a
high degree of overlap in their patterns of structural alterations makes forward
inference-based analyses less suitable for identifying brain areas whose alteration is
specific to a certain pathology. In the forward inference-based analyses, in fact, it is
impossible to distinguish between areas that are altered by the majority of brain dis-
orders and areas that are specifically affected by certain diseases. To address this
issue and allow the identification of highly pathology-specific altered areas we used
the Bayes' factor technique, which was employed, as a proof of concept, on voxel-
based morphometry data of schizophrenia and Alzheimer's disease. This technique
allows to calculate the ratio between the likelihoods of two alternative hypotheses
(in our case, that the alteration of the voxel is specific for the brain disorder under
scrutiny or that the alteration is not specific). We then performed temporal simula-
tions of the alterations' spread associated with different pathologies. The Bayes' fac-
tor values calculated on these simulated data were able to reveal that the areas,
which are more specific to a certain disease, are also the ones to be early altered. This
study puts forward a new analytical instrument capable of innovating the methodo-
logical approach to the investigation of brain pathology.
K E YWORD S
alteration specificity, Alzheimer's disease, Bayes' factor, brain disorders, pain, reverse
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1 | INTRODUCTION
Studying the distribution of co-altered areas in the pathological brain
is fundamental to better understand how neuropathologies spread
and develop, as well as to improve categorizations and diagnoses
(Hyman, 2010). The psychopathological models in the Diagnostic and
Statistical Manual of Mental Disorders (DSM, American Psychiatric
Association, 2013) and the International Statistical Classification of
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Diseases (ICD, World Health Organization, 2007) consider both psy-
chiatric and neurological conditions as distinct clinical constructs with
different etiologies. However, growing evidence is challenging this
view (Buckholtz & Meyer-Lindenberg, 2012; Nolen-Hoeksema &
Watkins, 2011). For example, large-scale phenotypic studies and
etiological investigations suggest that brain disorders are frequently
characterized by polygenic inheritance with multiple small-effect risk
alleles causing a constant diffusion of genetic liability, thus ruling
out any rigid classification of mental illnesses (Buckholtz & Meyer-
Lindenberg, 2012; Gejman, Sanders, & Kendler, 2011; Krueger, 1999).
Comorbidity, too, defies rigid categorization. Co-occurrences of psy-
chiatric diseases are rather frequent than exceptional (Cauda et al.,
2017; Cauda et al., 2018; Goodkind et al., 2015; van den Heuvel &
Sporns, 2019); this large diversity in symptomatology, dimensionality
and comorbidity (Kessler et al., 2005; Krueger & Markon, 2011;
Markon, 2010) points to a profound revision of models of classification
(Krueger & Markon, 2006).
A transdiagnostic approach can meet this new need, as it is able to
highlight important differences and similarities in brain disorders. Sev-
eral studies already show that a variety of psychiatric and neurological
conditions preferentially target certain brain regions (Buckholtz &
Meyer-Lindenberg, 2012; Cauda et al., 2017; Cauda et al., 2019;
Cauda, Nani, Costa, et al., 2018; Cole, Repovs, & Anticevic, 2014;
Goodkind et al., 2015; Liloia et al., 2018; McTeague, Goodkind, &
Etkin, 2016). More specifically, Cauda et al. (2019) showed that most
of brain disorders are likely to produce anatomical alterations that
largely overlap with each other, thus demonstrating that there is a
common set of regions (such as the insula, the anterior cingulate cortex
(ACC), some of the prefrontal and anterior temporal areas) which is
altered by the majority of brain disorders (in these areas more than
90% of pathologies have at least one focus of alteration). In contrast,
there are very few brain areas specifically altered by one or a limited
number of diseases (Liloia et al., 2018). This large overlap of altered
regions makes them scarcely informative about the development of
neuropathological processes, because in these regions the alteration
pattern is rather nonspecific. Furthermore, analyses based on forward
inferences (Poldrack, 2006) cannot help us, as they tend to treat in the
same way both the areas having high or low specificity. Instead, an
approach based on Bayesian reverse inferences can extract relevant
information from patterns of altered regions. There are, however,
important issues that need to be addressed, which this study aims to
tackle. Let us see three points in more details.
First, using the anatomical likelihood estimation (ALE) values as
source data, it is possible to create, through a Bayesian reverse infer-
ence approach, a map of alterations caused by brain disorders, and
identify the areas, if any, that are more specific for these diseases.
Researchers generally apply forward inferences by asking what
are the areas affected by certain pathology; in our case, we are inter-
ested in reverse inferences by asking what are the pathological condi-
tions that might have produced a specific alteration pattern. The
probability that a specific pattern of gray matter (GM) alterations may
be related to a specific brain disorder is not equivalent to the probabil-
ity that a specific brain disorder may be related to a specific pattern of
GM alterations: P(GM alteration|brain disease) 6¼ P(brain disease|GM
alteration). The reason of the not equality of the relation between the
two probabilities could be due to various factors, such as noise,
incomplete knowledge of the anatomical and/or functional relation-
ship. To our best knowledge, this kind of calculus has never been tried
before on meta-analytical data of morphological alterations but only
on healthy subjects' task-based fMRI data (Poldrack, 2006, 2011;
Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). A study
(Sprooten et al., 2017), which tried a type of reverse inference over
functional data of psychiatric patients, was not based on a Bayesian
reverse inference, as authors applied a Chi squared test with the
Yates' correction on a cross tables diagnosis-by-region and tested
whether studies about different psychiatric conditions report similar
results. The authors, in sum, calculated a form of correlation between
the number of studies of the pathology-by-region and those of
another pathology.
Second assuming the equiprobability of the priors, the calculus of
the Bayes' factor (BF) index can measure the involvement of an
altered area in a brain disorder as well as avoid the potential bias of
the inhomogeneous representativeness of diseases within a database.
The possibility of the reverse inference from neuroimaging
data has been extensively explored (Hutzler, 2014; Machery, 2014;
Montagna, Wager, Barrett, Johnson, & Nichols, 2018; Poldrack,
2006, 2011, 2012; Poldrack & Yarkoni, 2016; Wager et al., 2015;
Woolrich et al., 2009). On the legitimacy of the method per se see
Lieberman and Eisenberger (2015), Poldrack (2013), Lieberman (2015),
Yarkoni (2015a), Yarkoni (2015b), ShackmanLab (2015), Wager
et al. (2016), Gelman (2017), Machery (2014) and Hutzler (2014). With
a pioneering study, Poldrack (2006) highlighted the difficulties in the
field of functional neuroimaging because the usual kind of inference
that can be applied to neuroimaging data is of the form: if a process
X is involved then the Y brain is activated, and also because it
has been highlighted that very specific patterns of activations associ-
ated with pathological conditions are extremely infrequent (Fox &
Friston, 2012; Poldrack, 2011). Difficulties in making a reverse infer-
ence correctly have been discussed in the debate raised after the
publication of Lieberman and Eisenberger (2015) (Gelman, 2017;
Lieberman, 2015; Poldrack, 2013; ShackmanLab, 2015; Wager
et al., 2016; Yarkoni, 2015a, 2015b), who claimed that activity of the
anterior dorsal cingulate is selective for pain. These findings, however,
have been criticized (Gelman, 2017; Lieberman, 2015; Poldrack, 2013;
ShackmanLab, 2015; Wager et al., 2016; Yarkoni, 2015a, 2015b).
To better assess the involvement of a certain brain activation in a
cognitive process we propose to use the BF index (Jeffreys, 1961),
which is the ratio between the likelihoods of two alternative hypothe-
ses. The choice of prior probabilities is the most complex issue in the
Bayesian approach to meta-analytical data. Priors are generally set to
0.5, so that neither hypothesis P(H1) nor hypothesis P(H2) is privileged,
where H1is the hypothesis of specificity and H2 the hypothesis of
nonspecificity, respectively. It should be noted that with a sufficient
amount of data, as it is our case, the BF should converge to the value
“true,” even though the priors are supposed to be equiprobable. It is
plausible that, even though you and I can have different prior beliefs,
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more often we will agree over the form of the likelihood, so that, if we
gather enough data, the posterior will become very close (Lee, 2012).
In any case, to avoid the introduction of prior densities regarding
the parameters, and to assess whether or not the use of inhomoge-
neous data may produce incorrect BF values, we propose to apply the
Schwarz criterion (Kass & Raftery, 1995; Schwarz, 1978), which, for
large samples, can be considered as an approximation of the logarithm
of BF. As postulated by the Schwarz criterion, our hypothesis is that
the BF values, calculated with equiprobable priors, converge to the
Bayesian information criterion (BIC) if they do not suffer from the bias
due to the inhomogeneity of the sample.
Third, considering neuropathology in its temporal progression,
the BF index can detect which cerebral areas are likely to be altered
early.
As alterations develop from few to many (Cauda et al., 2018),
reverse inferences may identify as more specific to a certain brain dis-
order the areas that are affected early. Theoretically, the maximum
level of overlap between altered regions reaches its limit when all the
brain is affected. In this hypothetical case, each brain pathology would
alter most of the cerebral areas. So, when abnormalities gradually
spread (Fornito, Zalesky, & Breakspear, 2015; Goedert, Masuda-
Suzukake, & Falcon, 2017; Iturria-Medina & Evans, 2015; Yates, 2012;
Zhou, Gennatas, Kramer, Miller, & Seeley, 2012), the overlap of alter-
ations caused by different pathologies will be greater and greater, thus
reducing the degree of specificity of the areas that are progressively
more altered (for an infographic see Figure S4). The capacity of the BF
index to highlight more informative altered regions was tested by
applying the calculus on simulations of diseases with different stages
of alteration spread.
2 | MATERIALS AND METHODS
As a proof of concept, we put forward a map based on Bayesian
reverse inference of the two most represented brain diseases in the
BrainMap database (http://brainmap.org/), namely schizophrenia
(SCZ) and Alzheimer's disease (AD).
BrainMap is an online open access database of published func-
tional and voxel-based morphometry (VBM) experiments that reports
both the coordinate-based results (x,y,z) in standard brain space
(Talairach or MNI) and a hierarchical coding scheme of meta-data con-
cerning the experimental methods and conditions (Fox et al., 2005;
Fox & Lancaster, 2002; Laird, Lancaster, & Fox, 2005; Vanasse
et al., 2018). At the time of the selection phase (April 2018), BrainMap
included meta-data associated with more than 4,000 publications,
containing over 19,000 experiments, 148,000 subjects and 149,000
coordinate-based results.
2.1 | Selection of studies
First, we queried the VBM BrainMap database sector (Vanasse
et al., 2018). By means of the software application Sleuth (v.2.4), we
employed a double systematic search to retrieve the eligible voxel-
based results for each of the two brain disorders of interest. The sea-
rch algorithms were constructed as follows:
For the meta-analysis of SCZ:
SCZ QUERY A) [Experiments Context IS Disease] AND [Experiment
Contrast IS Gray Matter] AND [Experiments Observed Changes IS
Controls>Patients] AND [Experiments Observed Changes IS Con-
trols<Patients] AND [Subjects Diagnosis IS Schizophrenia];
SCZ QUERY B) [Experiments Context IS Disease] AND [Experiment
Contrast IS Gray Matter] AND [Experiments Observed Changes
IS Controls>Patients] AND [Experiments Observed Changes IS
Controls<Patients] AND [Subjects Diagnosis IS NOT Schizophrenia].
For the meta-analysis of AD:
AD QUERY A) [Experiments Context IS Disease] AND [Experiment
Contrast IS Gray Matter] AND [Experiments Observed Changes IS
Controls>Patients] AND [Experiments Observed Changes IS Con-
trols<Patients] AND [Subjects Diagnosis IS Alzheimer's Disease];
AD QUERY B) [Experiments Context IS Disease] AND [Experiment
Contrast IS Gray Matter] AND [Experiments Observed Changes
IS Controls>Patients] AND [Experiments Observed Changes IS
Controls<Patients] AND [Subjects Diagnosis IS NOT Alzheimer's
Disease].
Therefore, two researchers screened all the identified articles in
order to ascertain that: (a) a specific whole-brain VBM analysis was
performed, (b) a comparison between pathological sample and healthy
control participants was included, (c) GM decrease/increase changes
in pathological sample were included, (d) locations of GM changes
were reported in a definite stereotactic brain space (i.e., Talairach
or MNI).
On the basis of the aforementioned criteria, we included in our
analyses: 114 articles, for a total of 147 experiments, 1754 GM
changes and 4,944 subjects (SCZ QUERY A); 693 articles, for a total
of 1,211 experiments, 9,353 GM changes and 41,746 subjects (SCZ
QUERY B); 55 articles, for a total of 83 experiments, 961 GM
changes and 1,297 subjects (AD QUERY A); 760 articles, for a total
of 1,277 experiments, 10,151 GM changes, and 49,194 subjects
(AD QUERY B). Descriptive information of interest and meta-data of
GM changes were extracted from each selected article (see Table S1
for detailed information about the description and distribution of
the VBM data set included in the meta-analysis). In order to facili-
tate subsequent analyses, coordinate-based results from MNI ste-
reotactic space were converted into Talairach space by using
Lancaster's icbm2tal transformation (Laird et al., 2010; Lancaster
et al., 2007).
The selection of studies was performed according to the pre-
ferred reporting items for systematic reviews and meta-analyses
(PRISMA) Statement international guidelines (Liberati et al., 2009;
Moher, Liberati, Tetzlaff, & Altman, 2009). The overview of the selec-
tion strategy is illustrated in Figure S1 (PRISMA flow chart).
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2.2 | ALE and creation of the modeled
activation maps
We performed an ALE using the random effects algorithm of
GingerAle (v.2.3.6, http://brainmap.org/ale) (Eickhoff et al., 2009;
Eickhoff, Bzdok, Laird, Kurth, & Fox, 2012; Turkeltaub et al., 2012).
The ALE is a quantitative voxel-based meta-analysis technique capa-
ble of providing information about the anatomical reliability of results
through a statistical comparison on the basis of a sample of reference
studies from the existing literature (Laird et al., 2005).
To describe the theory behind the ALE method we follow the
description and nomenclature used in Samartsidis, Montagna, Nichols,
and Johnson (2017). The idea of ALE is to model, for each voxel, the
probability that it is a true location of a focus reported as Gaussian
distribution centered on it. Given a study i, the map based on a single
location xik is given by:
Lik vð Þ= cϕ3 vjxik ,σ2I
 
with ϕ3(x; μ, Σ) is a three-dimensional Gaussian distribution with mean
and covariance μ, Σ evaluated at x3, I is the identity matrix and c is
a normalization constant ensuring that the sum of ϕ3 over voxels
equals to one. In this way Lik(v) is the probability that the voxel v is the
true location of xik.
The only free parameter is σi, which is determined in an empirical
study by Eickhoff et al. (2009) associating the number of subjects ni in
each study with the SD σi.
The next step of the ALE procedure is to merge the maps Lik in a
single study map Li. This map quantifies the probability of how the





1−Li vð Þð Þ ð1Þ
This formula represents the probability that one of the closest
activations is located in voxel v.
The significance test of ALE is obtained using a Monte Carlo pro-
cedure. For each location, multiple statistics are created by sampling





1−Li vð Þð Þ
in which v* is drawn uniformly from all possible brain locations. The
null distribution can be used to calculate p-values uncorrected or not,
see Eickhoff et al. (2012) for a more detailed description.
2.3 | Reverse inference and Bayes' factor
The framework of the reverse inference is the Bayes' theorem. In gen-
eral, reverse inference in neuroimaging provides information about
the involvement of brain areas in cognitive processes. Through a
reverse inference we can infer the posterior probability of a certain
cognitive process M starting from a pattern of brain activation A. This
inference is based on the conditional probability or likelihood P(A|M)
and a prior probability P(M), that is, the probability we have before
acquiring any clues on brain activations. Neuroimaging data can pro-
vide information on the likelihood of M given A.
The same reasoning still holds if we substitute “brain activity A"
with “brain alteration A” and “cognitive process M" with “brain disor-
der M". In this case, the reverse inference leads us to infer the poste-
rior probability of a pathology P(M|A) from a certain pattern of brain
alterations P(A|M) using the Bayes' theorem:
P MjAð Þ= P AjMð ÞP Mð Þ
P AjMð ÞP Mð Þ+ P Aj¬Mð ÞP ¬Mð Þ ,
where the ¬ symbol is the logical NOT.
Therefore, given the brain alteration A and the prior probability
that the disease M occurs, it is possible to assess the posterior proba-
bility that M occurs on the basis of A. This choice depends on the
information that we know before calculating the likelihood. In the lit-
erature, there is no general consensus as to how this choice should be
made—for a review of the several proposals put forward to address
this point see Carlin and Louis (2008).
The Bayesian approach to testing hypotheses has been developed
by Jeffreys (1961) as part of his scientific program to study inference.
Within this approach, given two competing hypotheses, the statistical
models represent the probability that data are in accord with one
or the other hypothesis and the Bayes' theorem is used to determine
the posterior probability of the two hypotheses. By calculating the
ratio between the two hypotheses we obtain a relation that can be
expressed in words as “Posterior odds = Bayes' Factor × prior odds”.
The BF is the ratio between the posterior and prior odds and rep-
resents a summary of evidence in favor of one of the two hypotheses.
The BF is similar to a likelihood ratio. However, differently from the
likelihood ratio, in the Bayesian framework there is no necessity of
sampling the distribution to assess the sample, because all the infer-
ences are conditional on the sample at hand. The BF therefore is a
summary measure of the information contained in the data about the
plausibility of the model.
We will adopt an objective Bayesian reasoning in which we try to
introduce little prior knowledge into the problem. This perspective
leads to consider the priors ratio P(H1)/P(H2) to be 1, meaning that the
prior probability is equal. This position is reasonable because the
resulting BF can be corrected with other ratios if the priors change.
With this choice, we have that the likelihood ratio is equal to the pos-
terior ratio, which is an important step because in the case of specific-




1−P H1jDð Þ ð2Þ
according to which the BF is equal to the odd ratio of the posterior.
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The framework within which the BF can be calculated on the basis
of meta-analytic data are the following. The likelihood of the data are
calculated as usual: the parameters of the Gaussian distribution are
obtained as a function of the number of subjects used in the experi-
ments under examination. That means that we do not use Bayes to
determine the posterior of the parameters: rather, in this context the
parameters are given and processed as usual in the ALE meta-analysis.
The Bayesian hypothesis test is applied to the successive steps of the
analysis. Therefore, the data used for the calculation of the BF are the
final ALE map obtained as usual with GingerALE software (Eickhoff
et al., 2009; Eickhoff et al., 2012; Turkeltaub et al., 2012).
For the analysis of VBM data the competing hypotheses were:
(a) the alteration of the voxel was specific for the brain disorder under
scrutiny; (b) or the alteration was not (¬) specific. We needed there-
fore to calculate the ALE maps derived from all the experiments in
which the detected alterations were associated with a specific brain
disorder and the ALE maps derived from all the experiments in
which the detected alterations were not associated with that specific
brain disorder. The final result of this process was the BF, a number
between [0, ∞] representing how much the data could support the
model Disease or ¬Disease.
Following Kass and Raftery (1995), the BF value can be inter-
preted as follows (Table 1).
2.4 | The Bayes' factor and temporal evolution of
brain diseases
Because the BF does not guarantee to highlight the earliest areas, but
it does so in virtue of statistical considerations, we run a simulation
to understand this aspect. As already showed (Cauda, Nani, Costa,
et al., 2018; Cauda, Nani, Manuello, et al., 2018; Crossley et al., 2014;
Iturria-Medina & Evans, 2015; Raj, Kuceyeski, & Weiner, 2012; Tatu
et al., 2018; Yates, 2012), neuropathological alterations are supposed
to be distributed across the brain following structural and functional
connectivity pathways. In order to simulate the alteration spread
related to a certain pathology we used the anatomical connectivity
matrix derived from Hagmann et al. (2008). Specifically, we used the
average fiber tract density between two brain areas, obtained from
healthy individuals with a parcellation of gray matter in 998 areas
(nodes). First, we simulated a target pathology, that is, AD; AD is the
ideal candidate because its areas of inception are well known. To do
so, we selected three nodes for each cerebral hemisphere on the basis
of the anatomopathological knowledge about AD (Braak & Del
Tredici, 2011). These six nodes were selected because of their prox-
imity to the transentorhinal cortex, which is known to be one of
the earliest sites of neurofibrillary deposition in AD (Braak, Alafuzoff,
Arzberger, Kretzschmar, & Del Tredici, 2006), and were used as
starting points for a simulated pathological spread. The model of simu-
lation was based on the diffusion equation already applied in Cauda,
Nani, Manuello, et al. (2018), which is the following:
dx tð Þ
dt
= −βLx tð Þ
where x is the concentration of the disease factor, β is the diffusivity
constant controlling propagation speed and the matrix L is the
Laplacian graph defined as:
L= I−Δ−1=2EΔ1=2
in which E is the matrix of the edges representing the connection
strength between nodes and Δ is the diagonal matrix with δi =
P
jeij as
the ith diagonal element. The solution of this equation is:
x tð Þ= exp −βLtð Þx0
This formula describes the evolution of an initial configuration
x0. The initial condition determines where the pathology begins to
spread, that is, which nodes are the earliest to be altered. Thus, by
considering different initial conditions, it is possible to simulate differ-
ent temporal evolutions of brain diseases. The entire temporal span of
the alterations' spread was subdivided in 1000 time points (arbitrary
units), from the initial condition (in which few nodes are altered) to
the state of equilibrium (in which all the nodes are altered). After
obtaining the diffusion data, we randomly selected for each simulation
100 time points so as to have a simulated picture of the uneven distri-
bution of pathological alterations. In each of these time points we
analyzed for every node the degree of its alteration; the nodes that
showed a degree of alteration over a predetermined threshold were
considered as being actually altered. Subsequently, every selected
time point with its surviving altered nodes was treated as an experi-
ment, thus generating different MA maps obtained from simulated
patients (from 6 to 20); all these MA maps were eventually united in
an ALE map.
To simulate other possible pathologies (up to 30), we selected for
each disease six bilateral nodes (three for each side) that were used to
study the temporal evolution of the alterations' spread. Overall, we
generated 1,000 time points for every simulated disease. As we did
for the target pathology, we randomly selected 100 time points, to
analyze the uneven distribution of alterations in different temporal
series. Simulating different number of patients (from 6 to 20), each
time point generated an MA map, which was united with the other
MA maps of the other time points in an ALE map. Finally, the MA
maps obtained from the target pathology (i.e., AD) and those obtained
from the other simulated diseases were used for the BF calculus.
TABLE 1 Bayes' factor points associated with different forces of
evidence
Bayes' factor (BF) Force of evidence
1 to 3 Not worth more than a mere mention
>3 to 20 Positive
>20 to 150 Strong
>150 Very strong
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2.5 | Validation
To assess the efficacy of our algorithm we have performed an analysis of
reverse inference on fMRI data about pain tasks obtained from the
BrainMap database; this analysis has been already carried out by Yarkoni
et al. (2011), and its results are also available on the Neurosynth platform
(core tools) as well as in Yarkoni (2015b). We made the following two
queries in the functional BrainMap database sector (April 2018):
A - PAIN) [Experiments Context IS Normal Mapping] AND [Experiments
Activation IS Activation Only] AND [Subjects Diagnosis IS Normals]
AND [Experiments Imaging Modality IS fMRI] AND [Experiments Par-
adigm Class IS Pain Monitor/Discrimination];
B - NO PAIN) [Experiments Context IS Normal Mapping] AND [Experi-
ments Activation IS Activation Only] AND [Subjects Diagnosis IS Nor-
mals] AND [Experiments Imaging Modality IS fMRI] AND
[Experiments Paradigm Class IS NOT Pain Monitor/Discrimination].
We retrieved 81 articles, for a total of 261 experiments, 2,604
foci and 1,157 subjects (QUERY A); and 3,141 articles, for a total of
10,209 experiments, 87,409 foci, and 58,367 subjects (QUERY B) (see
Figure S2 PRISMA flow chart for the overview of the selection strat-
egy, Table S2 for the sample characteristics and Table S3 for more
information about the selected fMRI data set, respectively).
From the data retrieved with Sleuth 2.4, we calculated the ALE
for the condition “pain” and for the condition “no-pain.” On the basis
of the priors p(Hi) = 0.5, i = 1, 2, we determined the posterior probabil-
ity and then the BF was determined as in (2), where in our case D
means the voxel v, so that the posterior, was defined as:
P H1jvð Þ= P vjH1ð ÞP vjH1ð Þ+ P vjH2ð Þð Þ
where P(v|H1) is the likelihood obtained by Equation (1) under the
“pain” condition and P(v|H2) is the likelihood obtained in the “no pain”
condition. The results of our analysis were compared visually with
those of Poldrack (2006) as they are illustrated in Figure 2 of his study
(Poldrack, 2006) as well as with the results of an association map pro-
duced by Neurosynth (Yarkoni et al., 2011). Indeed, the standard out-
put of Neurosynth is not actually a BF map, so comparisons are
necessarily to be made by analogy.
2.6 | Validation of the priors: Schwarz criterion
and Bayes' information criterion
To test and consolidate the results obtained for the specificity with
meta-analytic data we used a different method that do not use the
prior as in the BF obtained in the previous section. It is possible to
avoid the introduction in the model of the prior density with the help
of the following formula:
S= logP DjH1ð Þ− logP DjH2ð Þ− 12 d1−d2ð Þlog nð Þ ð3Þ
where θk are the estimations with regard to the different hypotheses
Hk, dk is the dimension of θk, and n is the numerosity of the sample.
If n ! ∞, it is possible to show the validity of the following relation,




The Schwarz criterion, therefore, tends to the BF. If we consider
the BIC, which is defined as:
BIC = d log nð Þ−2log P Djθk ,ð Þð Þ
we can see that, from (3), minus twice the Schwarz criterion is the dif-
ference between the BIC of the two hypotheses—for an in-depth
description of this theme see Kass and Raftery (1995). Finally, if we
multiply the BIC for minus 0.5, we obtain the S value, which can be
compared with the BF. As pointed out in the introduction, we can
observe that the BIC depends on the number of samples (log(n)); it is
therefore a way of verifying whether or not the choice of 0.5 as prior
is correct for the BF calculus. If we obtain convergent results, we
would be relatively confident that the rationale for choosing equi-
probable priors is, at least with large samples, sound.
2.7 | Stability against sample unbalances: Sample
unbalance compensation
To minimize the potential bias of the inhomogeneous representative-
ness of brain disorders in the database, we generated a single sample
for every brain disease by determining an ALE map of all the experi-
ments about that specific disease. BF maps constructed with this
compensatory procedure were correlated to the original BF maps
obtained without compensation.
2.8 | The file drawer problem or robustness
against noise: Fail-safe
The “fail-safe” technique is frequently used in classical meta-analyses
of both medical and psychological studies. It was first introduced by
Rosenthal (1979) and a specific approach for assessing the robustness
of results against potential publication bias in ALE meta-analyses was
recently developed by Acar, Seurinck, Eickhoff, and Moerkerke (2018).
This method presumes that there are unpublished studies with
contra-evidence results, and consequently estimates the number of
these studies that can be added to the meta-analysis before results
get invalidated. In other words, the procedure requires to introduce
into the sample increasing amount of noise (i.e., unreported experi-
ments) in order to assess how statistically robust is the meta-analytic
result. Here the “fail-safe” technique has been used to address the
possibility that in BrainMap an amount of contra-evidence experi-
ments has not been stored.
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We used the code developed by Acar et al. (2018), which is
available on Github (https://github.com/NeuroStat/GenerateNull).
The procedure can be divided into two steps: noise generation and
robustness estimation. In the first step, the required amount of noise
experiments is obtained. It must be noted that in doing this, the algo-
rithm is constrained by the distributions of the number of foci and the
number of subjects of the real meta-analytic sample (i.e., experiments
retrieved from BrainMap). In other words, if the experiments in the
original meta-analysis had a sample-size between 10 and 20, and
reported between 10 and 20 foci (i.e., peak values) each, the simulated
experiments will also have a number of foci and subjects comprised
between 10 and 20. This lends the noise realistic features. The spatial
localization of peaks is then randomly sampled from the same gray
matter mask used in the ALE computation. In order to correctly esti-
mate the noise, the first step was repeated for each disorder sepa-
rately (i.e., AD, SCZ, and pain).
In the second step, the noise experiments and the original meta-
analytic sample are combined and fed into the ALE algorithm. Results
were tested for statistical significance with 1,000 permutations, as
implemented in GingerALE. In other words, the second step allows to
re-run the meta-analysis taking into account potential experiments
“remained in the drawer.” This procedure was iterated several times
(and for each of the three disorders considered) adding an increasing
amount of noise experiments (between k2 and 3k, where k is the num-
ber of the original studies). The ALE maps obtained at each level
where then combined to show the robustness of the effect (i.e., the
amount of noise that can be added before the true effect detected by
ALE loses statistical significance). There are currently no normative
values to interpret the fail-safe results in the context of ALE meta-
analysis applied to VBM experiments. As pointed out by Acar et al.
(2018), the minimum amount of injected noise of 5k+10 proposed by
Rosenthal (1979) for behavioral studies seems to be excessively high
to be extended to fMRI field. For the scope of the present work, we
considered 3k a reasonable upper bound. Taking SCZ as an example,
this means that for each of the 114 experiments included in the origi-
nal meta-analysis, three more experiments remained unreported (for a
total of 342).
Finally, A BF map was computed for each level of noise, and cor-
related with the BF map originally obtained for the set of real experi-
ments (a threshold level of three BF points was used for each map).
This allowed us to test the degree to which BF is affected by potential
not included experiments.
3 | RESULTS
3.1 | Bayes' factor
3.1.1 | Comparison with previous results
To test our algorithm, we replicated the analysis performed in Yarkoni
et al. (2011). Figure 1 (middle and bottom rows, and Table S6) shows
the results of the reverse inference on pain tasks data queried from
BrainMap as well as the association map provided for “pain” by
F IGURE 1 Top: Base rates reports of how many pathologies of the VBM BrainMap database cause alterations in every area of the brain.
Areas highlighted in red are those in which more than the 90% of pathologies cause at least an alteration. Middle and bottom: Association test
(expressed in z points) over the term ‘Pain’ performed with Neurosynth and compared with a Bayes' factor (expressed in normalized BF values)
map calculated with equiprobable priors over BrainMap data (see Table S6 for the specific numeric visualization). Left panel: Radar map illustrating
the comparison between the network-based decomposition of previous results expressed in z mean points (Neurosynth) and Bayes' factor values
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F IGURE 2 Top right: Bayes' factor (BF) map of Alzheimer's disease calculated with equiprobable priors over BrainMap data. Top left: Bayes'
factor map of Alzheimer's disease calculated with equiprobable priors over BrainMap data, compensated for the different representativeness of
pathologies in the database. Bottom right: Bayes' factor (BF) map of schizophrenia calculated with equiprobable priors over BrainMap data.
Bottom left: Bayes' factor map of schizophrenia calculated with equiprobable priors over BrainMap data, compensated for the different
representativeness of pathologies in the database. Middle: Radar maps illustrating the comparison between the network-based decomposition of
previous results expressed in mean Bayes' factor values. Bayes' factor maps are expressed in normalized BF values. See Table S4 and S5 for the
specific numeric visualization
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Neurosynth. Our results are very similar, albeit more conservative,
to those of Neurosynth as well as to those shown by Yarkoni
(Yarkoni, 2015b; Yarkoni et al., 2011). However, differences are to be
expected, given the variability of input data and the methods used
for constructing the maps (ALE vs. MKDA; see Wager, Lindquist, &
Kaplan, 2007). Moreover, Neurosynth does not provide a BF map but
an association map expressed in z scores (for a detailed discussion see
Yarkoni, 2015b; Yarkoni et al., 2011).
3.1.2 | Alzheimer's disease and schizophrenia
Overall, the maps of specificity reveal that the two most represented
pathologies in BrainMap are characterized by certain areas with posi-
tive BF values (see Table 1 and Supplementary Results in the Supple-
mentary Material). It should be noted that the right parahippocampus
is the only region in AD reporting a strong BF value (i.e., BF 21),
whereas middle positive BF values (i.e., BF between 10 and 20) are
exhibited by the left inferior parietal lobule and the right caudate tail.
Others positive values (i.e., BF between 4 and 9) in AD were found in
the bilateral hippocampus-amygdala complex, in the right posterior
cingulate cortex and supramarginal gyrus, as well as in the left supe-
rior temporal gyrus and superior parietal lobe (see Table S5 for a
numeric visualization and Figure 2 top right). The resulting specificity
map for the SCZ condition shows middle positive BF values in the
right postcentral and inferior frontal areas, in the left orbital gyrus,
superior frontal and temporal areas. Other positive BF values in SCZ
were found in the bilateral precunei, in the right uncus, inferior/middle
temporal gyri and in the left medial frontal areas (see also Table S4
and Figure 2 bottom right).
3.1.3 | The Bayes' factor and temporal evolution
of brain diseases
Figure 3 shows the temporal evolution of the simulated target pathol-
ogy (i.e., AD), the foci from which the pathology begins to spread (top
left panel), and the temporal evolution of all the other simulated pathol-
ogies used for statistical comparison (middle panel). The figure also illus-
trates the BF map calculated on the synthetic data (bottom panel), as
well as the comparison between the areas showing a BF > 10 and the
starting points (nodes) of the simulated target pathology (right panel).
3.2 | Validation
3.2.1 | Sample unbalance compensation
Original BF maps obtained without compensation (Figure 2 top right
and bottom right) and those obtained with the compensatory procedure
F IGURE 3 Bayes' factor (BF) and the temporal evolution of pathologies. Top left: Starting nodes of the target pathology (Alzheimer's disease,
AD). Middle: Temporal evolution (expressed in arbitrary time points) both of the target pathology and of all the other simulated pathologies.
Colors from green to violet show the areas that are altered from early to late phases of the simulated pathological spread. Bottom: BF values
calculated on synthetic data. Right panel: Comparison between the areas showing a BF > 10 and the starting points of the simulated target
pathology
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(Figure 2, top left and bottom left) show high correlation values: 0.82
for AD and 0.74 for SCZ, respectively (see Figure 2, middle panel).
3.2.2 | Bayes' information criterion
To test how much the choice of equiprobable priors can influence
the BF values, we compared the BIC with the BF map related to
pain and generated with equiprobable priors (Figure 4). Results
show that both the techniques produce maps that are extremely
similar to each other (r = 0.88). This high correlation leads us to
think that the choice of equiprobable priors does not bias the BF
calculus.
3.2.3 | Fail-safe
Compared to the results related to AD and SCZ, the ones related to
the pain condition are more vulnerable to the noise injections. In fact,
for the pain condition most of brain areas with significant BF values
do not survive after an amount of noise over 100% (Figure 5, left
panel). In this case, the most surviving areas are the sensorimotor and,
F IGURE 5 Left panel: Fail-safe results of the Bayes' factor calculated over pain data. Areas colored from blue to red show increasing
resistances to progressively greater injections of noise in the data set. Middle panel: Fail-safe results of the Bayes' factor calculated over
Alzheimer's disease data. Areas colored from blue to red show increasing resistances to progressively greater injections of noise in the data set.
Right panel: Fail-safe results of the Bayes' factor calculated over schizophrenia data. Areas colored from blue to red show increasing resistances to
progressively greater injections of noise in the data set
F IGURE 4 Right panel: Comparison between the results of the Bayes' information criterion (BIC), expressed in S value (see Methods section),
performed over the term 'Pain' and the Bayes' factor (BF) map calculated with equiprobable priors over BrainMap data. Left panel: Radar map
illustrating the comparison between the network-based decomposition of previous results expressed in mean BIC and BF values. Bayes' factor
maps are expressed in normalized BF values. See Table S6 for the specific numeric visualization
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to a lesser extent, the posterior insular. In contrast, AD and SCZ have
higher correlations even with great quantities of noise injection. In
particular, with regard to SCZ, the correlation is still at r = 0.67 after
an amount of noise of 300%, while with regard to AD, the correlation
is at r = 0.55 after an amount of noise over 150% (Figure 5, middle
and right panels). In the case of AD, the most surviving areas are those
associated with the posterior component of the default mode net-
work (DMN). In the case of SCZ, most of the areas with significant BF
values survive after huge noise injections, save for the most anterior
prefrontal areas. Figure 6 shows how the correlation between BF
maps, derived from AD, SCZ, and the pain condition and obtained
with and without noise, drops at r = 0.3 after an amount of noise
over 150%.
4 | DISCUSSION
In this study, we have applied a Bayesian reverse inference method to
map the pathological brain and identify its altered regions that are
specific to the two most represented disorders in BrainMap database
(i.e., AD and SCZ). This specificity is expressed in terms of BF, positive
values of which (>3, but rarely superior to 20) characterize the struc-
tural alteration profiles both of AD and of SCZ. In particular, the pos-
terior components of the DMN, the amygdalae, the hippocampus
and parahippocampus exhibit positive specificity in the BF map of
AD. Although the BF values of these areas are positive, they are not
strong and just the parahippocampus shows a BF that is slightly supe-
rior to 20 (see Figure S3 and Tables S4, S5, and S6).
With regard to AD, our findings are in accordance with well-
established research and have been also further supported recently by
our group (Manuello et al., 2018). Volumetric changes involving the hip-
pocampus/parahippocampus, and especially the entorhinal cortex, have
been repeatedly considered as relevant features in the development of
AD (Jack Jr. et al., 1997; Rabinovici et al., 2007; Whitwell et al., 2007).
In fact, the atrophy of the medial temporal lobe, generally involving the
amygdala (Poulin, Dautoff, Morris, Barrett, & Dickerson, 2011), is a sig-
nificant biomarker that helps predict the evolution from mild cognitive
impairment to AD (Devanand et al., 2007). Furthermore, resting-state
fMRI investigations provide evidence that AD is associated with a
decreased functional connectivity within the DMN (Zhu, Majumdar,
Korolev, Berger, & Bozoki, 2013). If we consider the progressive
tauopathy that characterizes AD, the typical involvement of both ento-
rhinal and parahippocampal districts may indicate that these are key
regions for the deposition of pathologic tau in this condition (Braak &
Braak, 1991; Braak & Del Tredici, 2011; Jack Jr. et al., 2018; Lowe
et al., 2018; Ossenkoppele et al., 2016; Price & Morris, 1999). The
deterioration of the mesial temporal (hippocampal/parahippocampal/
entorhinal) cortex, in association with the posterior portions of the
DMN, can be successfully identified by structural neuroimaging tech-
niques (both VBM and cortical thickness) with different outcomes for
F IGURE 6 Fail-safe results of the Bayes' factor (BF) of three data sets (i.e., pain, Alzheimer's disease, and schizophrenia) obtained from the
correlational values between the BF map calculated without injections of noise and BF maps calculated with progressively increasing injections of
noise. Colors from blue to red indicate increasing values of standard deviation between the r values calculated in the different runs of the fail-safe
procedure
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sensibility/specificity in comparison to normal isocortical atrophy (Diaz-
de-Grenu et al., 2014). The highest BF values in the parahippocampus
and the transentorhinal regions (Taylor & Probst, 2008) demonstrate
that high BF values are telltale signs of the cerebral areas that are the
earliest to be altered.
With regard to SCZ, we observe that the insula, the ACC, the ven-
tromedial prefrontal cortex, the dorsolateral prefrontal cortex, and
the medial thalamus show an increased specificity compared to other
altered areas. The BF values of these areas are positive but not strong
(ranging between 3 and 20 points). In morphometric studies of SCZ,
the involvement of the insular cortex is frequently reported (Bora
et al., 2011; Brandl et al., 2019; Wylie & Tregellas, 2010). Also,
decreases in gray or white matter volumes have been observed in
both ACC and various sites of the prefrontal cortex (Baiano et al.,
2007; Ellison-Wright, Glahn, Laird, Thelen, & Bullmore, 2008; Glahn
et al., 2008; Honea, Crow, Passingham, & Mackay, 2005; Kim, Kim, &
Jeong, 2017; Koo et al., 2008; Narr et al., 2005; Nesvag et al., 2008).
The thalamus, too, is supposed to play a role in SCZ, on the basis of
its many connections with several brain structures, especially with
the prefrontal cortex (Alelu-Paz & Gimenez-Amaya, 2008; Pergola,
Selvaggi, Trizio, Bertolino, & Blasi, 2015; van Erp et al., 2016). The
complex GM alterations reported by scientific literature in patients
with SCZ (in particular in insular and prefrontal regions) (Kelly
et al., 2018; van Erp et al., 2018) principally impact on areas whose dis-
ruption is directly associated with episodes of psychosis and their
long-term outcome (Palaniyappan et al., 2016; Zuliani et al., 2018),
as well as with cognitive ability and the development of cognitive dis-
turbances (Sasabayashi et al., 2017). The specific structural pattern,
characterized by altered cortical thickness/volume associated with
a perturbed cortical gyrification (both hyper- and hypogyria), reflects
the involvement of a strong genetic or very early developmental back-
ground (Docherty et al., 2015; Spalthoff, Gaser, & Nenadic, 2018).
For all these reasons, SCZ can be considered as a model of neu-
rodevelopmental disorder with high heritability (Andreasen, 2010;
Hilker et al., 2018).
The analysis of the alteration specificity put forward in this study is
complementary to the transdiagnostic alteration patterns observed in
previous investigations (Buckholtz & Meyer-Lindenberg, 2012; Cauda
et al., 2017; Cauda, Nani, Costa, et al., 2018; Cole et al., 2014; Goodkind
et al., 2015; McTeague et al., 2016; Poldrack, 2006, 2011; Yarkoni
et al., 2011). These two approaches provide an overarching picture of
the pathological brain, which is of great interest for a better understand-
ing of how neuropathological processes affect this organ. Interestingly,
although many cerebral areas are altered by the majority of brain dis-
eases, patterns of alterations that seem specific to certain conditions
can emerge. The study of these typical profiles of alterations promises
to give valuable insights for the improvement of our clinical tools.
4.1 | The temporal evolution of brain diseases
It should be noted that when a specific brain disease (especially
the neurodegenerative ones) is in its terminal stages, many areas of
the brain would be affected. Therefore, if neuropathologies were
studied during their advanced developments, they would show a
great overlap of alterations. Differently from the discipline of patho-
logical anatomy, which carries out postmortem studies of the human
brain, neuroimaging techniques usually examine mixed pathological
populations exhibiting different phases of brain degeneration. More-
over, many studies are conducted on patients after their first diagno-
sis. These samples of individuals, therefore, are not expected to have
areas showing great overlap of alterations (Cauda et al., 2019).
Clearly, the simulation shows that the BF calculus can capture,
albeit with some approximation, the earliest points of the simulated
spread. In other words, the BF calculus is able to identify the areas
that are more precociously altered and, therefore, to distinguish
between them and those regions that are affected later. This result
emphasizes the importance to use reverse inference techniques for
studying the anatomical alterations caused by brain diseases, as these
techniques can provide a window into the initial stages of neuropath-
ological development, thus making possible the identification of pat-
terns of alteration spread as specific biomarkers of the early phases of
brain disease in view of patients' selection for disease-modifying clini-
cal trials (Pratt & Hall, 2018; Rohrer et al., 2015; Weiner et al., 2017)
as well as for assessing the efficacy of therapies (Cummings, Ritter, &
Zhong, 2018; Lawrie, O'Donovan, Saks, Burns, & Lieberman, 2016;
Marizzoni et al., 2018).
Indeed, with regard to AD and SCZ, it has been possible to identify
with our Bayesian reverse inference method not only the areas that
appear to be early affected (Braak & Del Tredici, 2011; Nenadic
et al., 2015) but also the sites of the main pathological alterations of
these two conditions, which are characterized by tauopathy and com-
plex structural alterations related to a genetic/neurodevelopmental
background (Jack Jr. et al., 2018; Spalthoff et al., 2018). For instance,
analyses of real data about AD have revealed that the parahippocampus
is the area with the strongest BF values (superior to 20; see Table S5), a
result that is in line with well-established scientific evidence (Taylor &
Probst, 2008).
This result supports well the hypothesis that high values of BF
might be proportional to the degree of alteration earliness exhibited
by those areas. Furthermore, the conceptual implication suggested by
high BF values deserves attention: in fact, the more specific is a brain
area for a disease, the greater the likelihood for that area to be preco-
ciously involved in the progression of the disease. Therefore, although
the BF calculus cannot exactly pinpoint the very first starting site of a
neuropathological process, it can identify the areas that are probably
affected early and differentiate them from those that appear to be
affected later.
4.2 | Validation
The analyses carried out in this study to understand how a sample
that is not uniformly balanced could bias the BF results, along with
the choice for setting the priors, have led us to think that the entity
of the potential biases is not as serious as to invalidate the BF
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calculus. In fact, the strategies used to overcome those difficulties,
both in the case of the compensation of the inhomogeneity of the
sample and in the case of the choice of the priors, have produced
results very similar to those obtained without these procedures. Still,
further research is needed to finally solve these problems. Especially
with regard to the choice of the priors, we need further investigations
with the help of empirical as well as Bayesian empirical techniques
for their calculus.
The fail-safe analysis has showed that the BF results obtained
from the anatomical alteration data of AD and SCZ are rather solid, as
they survive after relevant injections of noise and they are not, there-
fore, strongly affected by publication bias (Acar et al., 2018). In partic-
ular, the results about SCZ are the best surviving, followed by the
results about AD and, at a certain distance, by the results about
the pain condition. Therefore, BF values obtained from VBM data
were more resistant to publication bias than those obtained from
functional data.
4.3 | Limitations
The analysis on meta-analytical data, which are characterized by a cer-
tain degree of deterioration as well as of spatial uncertainty, might
have increased the overlap between regions affected by different
pathologies and, as a consequence, reduced the capacity of revealing
small areas with high specificity. This aspect notwithstanding, the
necessity of using a huge repository, in which data of a large number
of brain disorders are stored, compels to adopt a meta-analytical
approach. Poldrack (2011) claimed that the BrainMap database might
be biased by the fact that the studies are introduced manually, as this
could lead to a partial sample of the literature. In contrast, the data-
base of Neurosynth, which uses an automated process for selecting
articles, should have a more comprehensive sample. We agree only in
part with this criticism. In fact, even if we could create an all-inclusive
database of task-based fMRI studies, the bias because the various
cognitive domains are not uniformly represented would not be defi-
nitely ruled out. This is because all the topics of research do not
have the same interest for the scientific community: for instance,
(i) some tasks or pathologies are more or less studied than others,
independently of their relative frequency; (ii) some other task or
pathologies are more difficult to study and, therefore, less investi-
gated; (iii) the automated selection process for introducing experi-
ments in a database can make classification mistakes, which are
sometimes more frequent than those occurring with a nonautomated
selection; (iv) Neurosynth does not differentiate between activation
and deactivation. In any case, the aim of the present study is not to
explore all the strengths and weaknesses of databases, such as
BrainMap or Neurosynth, but rather to propose solutions and try to
overcome the problems raised in the debate about the reverse
inference.
Although we have devised strategies to avoid the problem of the
inhomogeneity of the BrainMap samples, and though the inhomoge-
neous distribution of data concerns the priors regarding the
parameters of the likelihood model rather than the priors regarding
the hypotheses, the uneven representation of pathologies may none-
theless have biased some results of the reverse inference. However,
so far the use of BrainMap is the only way to create maps of GM
alterations capable of giving an overarching picture of the pathological
brain. As matter of fact, the frequency of distribution of pathologies in
a database cannot represent accurately the frequency of distribution
of pathologies in the real world. This is so because certain conditions
are more investigated than others, independently of their incidence in
the population, so that they are sampled with varying frequencies in
the literature. Moreover, BrainMap contains only a fraction of all the
neuroimaging literature about brain disorders and the addition of new
studies is not principally directed to reduce this inhomogeneity. So,
the amount of results that researchers report is inevitably related to
their expectations as well as to the fact that some research topics are
more prevalent than others; and the BrainMap database inevitably
reflects that bias. Furthermore, even though our model can exclude
possible two identical studies, it cannot control if more than one study
has been carried out on the big same data set, such as COBRE
(Calhoun et al., 2011) or ADNI (Wyman et al., 2013). As a conse-
quence, our estimates may be biased upwards. Nonetheless, the vali-
dation analysis through the BIC, the compensation of the base rates
of different pathologies, and the fail-safe technique have showed that
the potential biases of the sample are unlikely to invalidate our
results.
Since a choice about the prior must be made, on the basis of our
validation analyses and in absence of better strategies, we propose to
choose equal priors (i.e., 50%). Needless to say, even though our vali-
dation analyses are encouraging, equal priors have both strengths and
weaknesses; hopefully future procedures will provide better solutions.
In the meantime, however, we think that the choice of equal priors is
a valuable strategy and should be adopted. This would encourage the
use of reverse inference techniques for the study of alterations cau-
sed by brain diseases, a study that, in our opinion, is essential to better
understand the pathological brain, especially in light of the fact that
many brain areas are nonspecific to pathologies but, rather, exhibit a
great overlap of alterations. Indeed, in spite of the problems already
discussed, a study based on the reverse inference obtained from brain
alterations data are extremely interesting, as it allows the identifica-
tion of the areas that are more specific and/or precociously altered in
a certain pathology. This obviously does not allow sustaining that the
alteration of a certain area is strictly specific to just one pathology,
but certainly it allows to identify which areas, whose alteration is fre-
quently associated with more or less brain disorders, are more or less
specific and informative. In addition, we can compare results obtained
from different pathological processes with each other, as well as com-
pare different patterns of GM alteration associated with the same
pathology, so as to reach a pathological imprint that is more specific
to that pathology.
Finally, our simulations of alteration spreads related to different
pathologies are based on the premise that alterations move diffusively
along brain connectivity pathways. Although this underlying mecha-
nism has been confirmed by recent research (Cauda, Nani, Costa,
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et al., 2018; Cauda, Nani, Manuello, et al., 2018; Crossley et al., 2014;
Fornito et al., 2015; Iturria-Medina & Evans, 2015; Manuello
et al., 2018; Raj et al., 2012; Tatu et al., 2018; Zhou et al., 2012), it is
not the only one that might play a role in the alteration spread. More-
over, the contributions of different mechanisms can vary with regard
to the type of pathology affecting the brain, so that our simulations,
even though they offer in our view the best approximation to real
pathological spreads with the available data, do not pretend to grasp
all the complexities of the actual phenomenon.
Another criticism concerns the fact that over time patients
develop more diffuse structural abnormalities, so that the reliability of
an abnormality may become lower due to the nature of how the dis-
ease evolves. However, it seems plausible that a likelihood model
underlying the BF could explicitly represent the progression of the
disease by using the diffusion patterns employed here to simulate
data. Nonetheless, since this BF approach is able to make inferences
about the areas that are early altered, it should also be possible that
this phenomenon may be a feature of the data and not of this particu-
lar approach.
A further limitation is that the BF is calculated in a univariate man-
ner: each voxel or area is considered in isolation without taking into
account a possible influence of other areas or voxels. Currently we are
trying to develop an approach capable of considering a joint probability
in which more variables (voxels or areas) are taken into consideration;
this view, however, poses several methodological problems, which are
mostly related to the expansion of the parameters' space and, conse-
quently, to the difficulty in performing the calculation.
5 | CONCLUSION
Although transdiagnostic research provides evidence that many sites
of the brain are altered by several pathological processes, this study
shows that a Bayesian reverse inference is capable of identifying the
cerebral areas exhibiting a high alteration specificity to certain pathol-
ogies. This approach allows to distinguish between areas that are
altered by most of brain diseases and areas that are altered by a lim-
ited number of pathologies and, therefore, can be considered more
specific to a certain pathology. It is also capable of identifying the
areas that are likely to be affected early, thus opening a new window
into the in vivo study of the pathological brain. These findings offer
interesting prospects for better characterizing brain disorders, as well
as a new way to perform VBM meta-analyses, thus hopefully contrib-
uting to the intriguing quest for deciphering the complex landscape of
alteration patterns of the pathological brain.
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